Starpharma see positive results in ovarian cancer treatment

Company News

by Rachael Jones

Starpharma (ASX:SPL) has seen positive results with targeted DEO using antibody fragment in human ovarian cancer model.

Treatment with a novel HER-2 targeted DEP resulted in tumour regression and 100 per cent survival in the experiment.

This experiment used a novel antibody fragment, which, like a whole antibody, binds actively and selectively to a specific antigen.

Using antibody fragments instead of full-sized antibodies has a number of commercial and technical benefits which stem from their small size, high potency, stability and ease of manufacture.

Shares in Starpharma (ASX:SPL) are trading 1.82 per cent higher at $1.12.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.